• Pei Chen, Yu-Ling Zhang, Xiao-Lei Zhang, Ying Guo, and Pei-Pei Tang.
• Department of Basic Medical, Jiangsu College of Nursing, Huai'an, China.
• Medicine (Baltimore). 2024 Apr 5; 103 (14): e37681e37681.

ObjectiveTo evaluate the relationship between CXCL12/CXCR4 and the progress, prognosis of esophageal squamous cell carcinoma (ESCC), providing evidence for potential early diagnosis, clinical treatment, prognosis evaluation, and therapeutic target of ESCC.MethodsDatabases of PubMed, the Cochrane Library, Embase, and Web of Science were searched for the relationship between CXCL12/CXCR4 and clinicopathological characteristics and survival time of ESCC. Stata16.0 software was used to conduct meta-analysis.ResultsA total of 10 studies involving 1216 cases of patients with ESCC were included in our study. The results indicated that high-level expression of CXCR4 was significantly correlated with tumor differentiation [OR = 0.69, 95% confidence interval (CI): (0.50, 0.97)], tumor infiltration [OR = 0.39, 95% CI: (0.25, 0.61)], lymph node metastasis [OR = 0.36, 95% CI: (0.21, 0.61)], clinical stage [OR = 0.33, 95% CI: (0.24, 0.45)] of ESCC. The expression of CXCR4 was also significantly correlated with OS [HR = 2.00, 95% CI: (1.63, 2.45)] and disease-free survival [HR = 1.76, 95% CI: (1.44, 2.15)] in patients of ESCC after surgical resection. No significant relationship was observed between the expression of CXCL12 and the clinicopathological characteristics of ESCC.ConclusionCXCR4 might be a potential biomarker for the progress and prognosis evaluation, and therapeutic target for ESCC.Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.

13 keywords...

hide…